Data coverage, completeness and provenance for PROTEOMICS INTERNATIONAL LABORATORIES LTD in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T04:18:59. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.1200 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.1175 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.1050 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.1200 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.1200 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/PIQ/prices · Price parameters and adjustment semantics
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.
Website: https://www.proteomics.com.au · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/PIQ/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 29 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 28 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 28 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 28 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 27 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/PIQ
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/PIQ/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/PIQ/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/PIQ/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/PIQ/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/PIQ
Free tier — instant API key. Built for AI agents.